Latest Peplin news
09-Jan-09
Positive results for Peplin's Phase IIb AK Trial read more
16-Dec-08
Peplin completes enrolment for its first phase III AK clinical trial read more
02-Dec-08
Form 10-Q - Quarterly Report read more
Registration statement including financial report read more
Contact us
Medical information
Telephone: +1-800-881-5754
Email:
Clinical trial information
Please refer to www.clinicaltrials.gov for trial information
Corporate information
Email: info@peplin.com
USA
6475 Christie Avenue
Suite 300
Emeryville, California 94608
Telephone: +1-510 653 9700
Facsimile: +1-510 653 9704
AUSTRALIA
Level 2, Brisbane Portal
1 Breakfast Creek Road
Newstead
Brisbane, Queensland 4006
Telephone: +61-7-3250 1200
Facsimile: +61-7-3250 1299
Abstracts
| Authors | Title | Reference |
|---|---|---|
| Freeman M, Oakley A, Siller G, Rosen R, Salmon P, Spelman L, Shumack S, Rubel D, Birchall N, Katsamas K | Study to determine the optimal tolerated regimen of ingenol mebutate (PEP005) gel for actinic keratosis of the face or face and scalp click here to view poster | Poster presented at Summer Academy 08, American Academy of Dermatology meeting, July 30 to August 03, 08, Chicago, IL, USA |
| Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stow DB, Welburn, P | Efficacy and tolerability of ingenol mebutate (PEP005) gel, 0.025% and 0.05%, for scalp and non-scalp actinic keratosis click here to view poster | Poster presented at Summer Academy 08, American Academy of Dermatology meeting, July 30 to August03, 08, Chicago, IL, USA |
| Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stow DB, Katsamas J | Safety and efficacy of ingenol mebutate (PEP005) gel, 0.025% and 0.05%, for actinic keratosis click here to view poster | Poster presented at Summer Academy 08, American Academy of Dermatology meeting, July 30 to August 03, 08, Chicago, IL, USA |
| Nowak, R | One weed to fight two killers click here to view article | New Scientist, 7 May 2005, No. 2498, page 16 |
| Siller G, Gebauer K, Welburn P | Treatment of actinic keratosis with PEP005 Topical Gel click here to view poster | Posted presented at ACADEMY 06, American Academy of Dermatology meeting, 26-30 July 06, San Diego, CA, USA |
| Ghoul A, Serova M, Benhadji KA, Metivier D, Cvitkovic E, Faivre S, Ogbourne SM, Welburn P, Hampson P, Chahal H, Lord J, Lokiec F, Calvo F, Raymond E. | PEP005, a novel ingenol angelate mediates apoptosis in human cancer cell lines by activation of p38 and MAPK pathways, via a PKC-dependent mechanism click here to view abstract | AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics November 14-18, 2005 - Poster Session A: Signal Transduction Modulators - A189 |
| Ghoul A, Serova M, Benhadji KA, Metivier D, Cvitkovic E, Faivre S, Ogbourne SM, Welburn P, Hampson P, Chahal H, Lord J, Lokiec F, Calvo F, Raymond E. | PEP005, a novel ingenol angelate mediates apoptosis in human cancer cell lines by activation of p38 and MAPK pathways, via a PKC-dependent mechanism click here to view poster | AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics November 14-18, 2005 - Poster Session A: Signal Transduction Modulators - A189 |
| Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Ogbourne SM, Welburn P, Faivre S, Lokiec F, Calvo F, Raymond E. | Antiproliferative activity of PEP005, a novelagent activates PKCdelta and inhibits PKCalpha, alone and in combination with cytotoxic agents in human solid tumor cancer cell lines click here to view abstract | AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics November 14-18, 2005 - Poster Session A: Signal Transduction Modulators - A188 |
| Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Ogbourne SM, Welburn P, Faivre S, Lokiec F, Calvo F, Raymond E. | Antiproliferative activity of PEP005, a novelagent activates PKCdelta and inhibits PKCalpha, alone and in combination with cytotoxic agents in human solid tumor cancer cell lines click here to view poster | AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics November 14-18, 2005 - Poster Session A: Signal Transduction Modulators - A188 |